Results of Cryoablation for Atrial Fibrillation Concomitant With Video-Assisted Minimally Invasive Mitral Valve Surgery

This is the author's manuscript

Original Citation:
Results of Cryoablation for Atrial Fibrillation Concomitant With Video-Assisted Minimally Invasive Mitral Valve Surgery / Marchetto, Giovanni; Anselmino, Matteo; Rovera, Chiara; Mancuso, Samuel; Ricci, Davide; Antolini, Marina; Morello, Mara; Gaita, Fiorenzo; Rinaldi, Mauro. - In: SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY. - ISSN 1043-0679. - 28:2(2016), pp. 271-280.

Availability:
This version is available http://hdl.handle.net/2318/1624226 since 2017-02-09T16:08:30Z

Published version:
DOI:10.1053/j.semtcvs.2016.04.006

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
Results of cryoablation for atrial fibrillation concomitant with video-assisted minimally invasive mitral valve surgery


Division of Cardiac Surgery, Department of Surgical Sciences, "Città della Salute e della Scienza di Torino" Hospital, University of Turin, Italy

*Division of Cardiology, Department of Medical Sciences, "Città della Salute e della Scienza di Torino" Hospital, University of Turin, Italy

Abstract word count: 241 words

No potential conflict of interest exist for all authors.

No funding was provided for this work.

Corresponding author:
Giovanni Marchetto, MD PhD
Email: giovanni.marchetto@libero.it
Department of Surgical Sciences, University of Turin
Division of Cardiac Surgery, Città della Salute e della Scienza Hospital,
Corso Bramante 88, 10126 Turin, Italy
Phone: +39-011-6335511 Fax: +39-011-6336130
GLOSSARY OF ABBREVIATIONS

- MIMVS: minimally invasive video-assisted mitral valve surgery
- AF: atrial fibrillation
- MV: mitral valve
- SR: sinus rhythm
- TOE: trans-oesophageal echocardiography
- PVs: pulmonary veins
- LA: left atrium
- PV: pulmonary vein
- ECG: electrocardiography
- SD: standard deviation
- PM: pace maker
- NYHA: New York Heart Association functional class
- OAC: oral anticoagulation
- SVC: superior vena cava
- LIPV: left inferior pulmonary vein
- LSPV: left superior pulmonary vein
- RIPV: right inferior pulmonary vein
- RSPV: right superior pulmonary vein
- IVC: inferior vena cava
- LV EF: left ventricular ejection fraction
- AP: antero-posterior
- SI: supero-inferior
- PAPs: systolic pulmonary artery pressure
- ACE-i: angiotensin-converting-enzyme inhibitor
Abstract

Objectives: Interest in minimally invasive video-assisted mitral valve surgery (MIMVS) is rapidly growing. Data on concomitant atrial fibrillation (AF) ablation to MIMVS are still lacking. The present study investigates the long-term results of AF cryoablation concomitant to MIMVS.

Methods: From October 2006 to September 2014, 68 patients with mitral valve (MV) disease (age 65.9±11.1 years, 34/68 males, Euroscore log 5.4±4.5) and drug resistant AF underwent MIMVS via right mini-thoracotomy and concomitant left sided AF endocardial cryoablation (Cryoflex Medtronic, Minneapolis, MN, USA). Patients were independently followed by cardiological outpatients visits and underwent electrophysiological study when indicated.

Results: Forty-four out of 68 patients (64.7%) underwent MV repair, 8/68 patients (11.8%) also received concomitant tricuspid valve surgery. One procedure was electively converted to full sternotomy (1.5%). Total clamp time was 97.6 ± 22.8 minutes. In March 2015, 60 patients were alive and completed the follow-up after a mean of 3.4±2.0 years following the procedure. Fourty eight patients (80%) presented sinus rhythm throughout the whole follow-up. Freedom from AF was respectively 96%, 87% and 72% at 1, 3 and 5 years. We recorded 2 pace-maker implants (3.3%). Three patients suffered symptomatic recurrences (2 atypical atrial flutter/1 atrial fibrillation) and underwent transcatheter ablation: all three patients remained in stable sinus rhythm for the remaining follow-up.

Conclusions: Given the favourable long term sinus rhythm maintenance rates of concomitant Cryoablation, MIMVS can also be offered to symptomatic AF patients. AF transcatheter ablation may easily avoid further symptomatic recurrences.

Key-words: atrial fibrillation, minimally invasive mitral, surgical ablation
Introduction

Interest in minimally invasive mitral valve (MV) surgery through a video-assisted mini-thoracotomy approach (MIMVS) is rapidly growing since when was first introduced in the mid-1990s [1]. A number of large studies have demonstrated the feasibility of performing MIMVS aiming to achieve similar safety and efficacy to conventional surgery with the added advantages of reduced trauma, improved cosmesis and shorter hospitalization [2,3].

Atrial fibrillation (AF) is the most common cardiac arrhythmia observed in clinical practice and confers an increased incidence of thromboembolic events and mortality [4]. A substantial increase in the incidence of AF has been reported in patients with indications for mitral valve surgery, and has also been demonstrated to be a profound risk factor for mortality [5]. The weight of this evidence has provided the impetus for the combination of surgical AF treatment and core cardiac surgical intervention, with the hope of synergistic improvements in both sinus rhythm (SR) maintenance and risk of morbidity and mortality [6, 7].

Concomitant surgical AF ablation and mitral valve surgery have proved to offer improved short- and mid-term SR maintenance compared to patients undergoing mitral valve surgery only. No differences were found between these two groups in terms of 30-day mortality, all-cause mortality, pacemaker implantation, stroke and thromboembolic events [8]. The advent of alternative energy sources has greatly simplified the original "cut and sew" technique to create transmural lines transforming surgical ablation into an easier, safer and faster procedure to be associated to MIMVS [9, 10]. Recently published guidelines have called for long-term follow-up studies on this topic [11-14]. However data on follow-up after concomitant AF ablation to MIMVS are still missing. The present study investigates the long-term results of AF cryoablation concomitant to MIMVS.
**Materials and methods**

is. From October 2006 to September 2014, out of 781 MIMV, the standard practice for MV disease in our Unit since October 2006, sixty-eight patients with concomitant drug resistant AF (13% paroxysmal, 87% persistent/long standing persistent) underwent video-assisted MIMV via right mini-thoracotomy through the 4th intercostal space and concomitant left sided AF cryoablation (Cryoflex Medtronic, Minneapolis, MN, USA). Each patient in our study signed a written informed consent to undergo surgical or transcatheter procedures. Preoperative characteristics are summarized in Table 1. Patients that had already performed a cardiac surgical procedure or a previous transcatheter AF ablation were not included in this series. The analysis was conducted in an Academic medical center where patients accept to share their clinical data in an anonymous form. The study was observational and did not add treatment or modify conventional surgical procedure for the specific clinical indication. **Surgical procedure.** After a full preoperative work-up that included aorto-iliac angiography/CT scan, the most appropriate out of the following three MIMVS approaches was selected: direct aortic cannulation and endoaortic balloon occlusion (EndoDirect, Edwards Lifesciences, Irvine, CA); femoral arterial cannulation either with endoaortic balloon occlusion (EndoReturn, Edwards Lifesciences, Irvine, CA) or with transthoracic clamp (Chitwood Clamp, Scanlan International Inc, St Paul, MN). All patients underwent video-assisted right minithoracotomy through the 4th intercostal space (range 4-6 cm). Double lumen endotracheal ventilation, transoesophageal echo (TOE) and CO2 surgical field flooding were also used in all patients. Venous return was routinely obtained by double cannulation (jugular and femoral) and myocardial protection by cold crystalloid cardioplegia [15, 16]. Concomitant left sided AF cryoablation (Argon based Cryomaze, Cryoflex Medtronic, Minneapolis, MN, USA) consisted of isolation of the pulmonary veins (PVs) and of the posterior left atrial (LA) wall between the veins by a "U" encircling cryolesion connected to the surgical paraseptal left atrial incision performed for mitral exposure, eventually creating the so-called "box lesion" (Figure 1). In
addition, a linear cryolesion (mitral line) was performed from the previously created box lesion to the mitral valve annulus to block conduction across the left atrial isthmus.

Electrophysiology study and transcatheter AF ablation. Under conscious sedation, and guided by a 3-dimensional electroanatomic mapping system (CARTO, Biosense Webster), the LA and PVs ostia were mapped measuring unipolar local voltage and detecting presence or not of PV isolation. In case of evidence of conduction gap between the PV and the atrium, antral pulmonary vein isolation was performed by radiofrequency ablation (Smartouch, Biosense Webster) aiming to complete PV isolation extending the surgical lesion set as demonstrated by circular mapping catheter (Lasso, Biosense Webster).

Clinical follow-up and event definition. After discharge patients were followed by cardiological outpatient visits as for lone AF transcatheter ablation protocol [11] including clinical examination and ECG at 3, 6, 12 months and then yearly. Holter monitoring was performed at least once in all patients. In case of symptom recurrence between follow up visits patients were reassessed by clinical examination, ECG and Holter monitoring. Electrophysiological study and transcatheter AF ablation were performed when indicated. Study period was closed in March 2015, all patients with at least 6 months follow up were included and reassessed with clinical examination, ECG and transthoracic Echocardiography.

Adverse events were classified according to the standardized definitions of the Society of Thoracic Surgeons/American Association of Thoracic Surgery/European Association of Cardiothoracic Surgery Guidelines for Reporting Morbidity and Mortality in Cardiac Valvular Operations and outcomes of AF cryoablation were reported following the HRS/EHRA/ECAS Expert Consensus Statement [11, 17]. A blanking period of three months was considered; following this interval any AF episode, persistent or paroxysmal, was registered as an event. All events were also classified as early (occurring within 30 days from the procedure) or late (>31 days after the procedure).
Statistical analysis. Categorical variables are reported as counts and percentages, while continuous variables as means and standard deviations (SD). Correlations between parameters and study groups were tested in cross tabulation tables by means of the Pearson Chi-Square or Fisher’s Exact Test and by one-way ANOVA respectively for categorical and continuous variables. McNemar’s test was used on paired categorical variables. Kaplan Meier curves were computed to describe AF free survival over time. A two sided p-value <0.05 was considered statistically significant; all analyses were performed with SPSS 20.0 (IBM Corp., Armonk, NY, USA).

Results

Forty-four out of 68 patients (64.7%) underwent mitral valve repair. By pathology, repair rates were 32/37 (86.5%) degenerative, 11/15 (73.3%) functional, and 1/16 (0.6%) rheumatic. Eight patients (11.8%) received also concomitant tricuspid valve surgery (Table 2). One procedure was electively converted to full sternotomy (1.5%) due to unexpected severe pleural adhesions and had an uneventful postoperative course. Total clamp time was 97.6±22.8 minutes. There was no reopening for any cause. 23/68 patients (33.8%) suffered AF relapses during hospitalization, 62 patients were discharged from the Unit in SR (91.2%). One in-hospital minor stroke was recorded (1/68, 1.5%); no patients required PM implantation in the acute phase. Early mortality was 1/68 (1.5%, due to respiratory complications following cardiac arrest resuscitated in the Ward). In March 2015 60 patients completed the follow-up after a mean of 3.4±2.0 years following the procedure. Study flow chart following the procedure is depicted in Figure 2. In this time frame no patients required redo surgery; valve repair and replacement reported favourable results (no MR 43, 63.3%; <2+/4+ 25, 36.7%). Three patients suffered from minor stroke (4.4%), while 1 patient (who relapsed on the second day after surgery with permanent AF) had a stroke (1.5%). Two (3.3%) patients required PM implantation during follow-up. Figure 3a illustrates echocardiographic parameters and functional class at baseline and at end of follow-up. Notably mean pulmonary artery pressure (from
46.0 to 36.1, p=0.006), antero-posterior left atrial diameter (from 54.5 to 49.2, p=0.012) and NYHA functional class (from 2.6 to 1.2, p<0.001) significantly decreased. Medications at baseline or discharge and end of follow-up are shown in Figure 3b. At 1-year follow-up 50% of patients discontinued amiodarone. Compared to discharge, significantly less patients were prescribed amiodarone at follow-up (56.3% vs. 18.8%, p<0.001) while more patients assumed beta-blockers (9.4% vs 68.8%, p<0.001). Oral anticoagulants were discontinued in a significant proportion of patients (84.6% on OAC pre-surgery vs. 56.4% on OAC at follow-up, p<0.001); in particular, 13/60 (21.7%) patients discontinued OAC at 1-year follow-up. At 1-year follow-up freedom from AF recurrences was 94.8%. Forty-eight patients (80%) presented SR throughout the whole follow up. Out of the 12 patients (20%) suffering relapses, 7 patients (58.3%) suffered paroxysmal episodes while 5 (41.7%) presented persistent AF (Figure 2). Seven patients (58.3%) relapsed as atypical atrial flutter while 5 (41.7%) as atrial fibrillation. Overall, three patients suffered symptomatic recurrences (2 atypical atrial flutter, 1 atrial fibrillation) and an electrophysiological study was indicated and performed in these patients (Figure 4). In two cases arrhythmia was sustained outside the lesion set while in one case a conduction gap was recorded. Following transcatheter ablation all three patients resulted in sinus rhythm for the remaining follow up. Freedom from AF relapses, stratified by AF type, is reported in Figure 5. Table 1 also describes preoperative characteristics of the patients population completing follow-up stratified by AF relapses at univariate analysis, highlighting that AF characteristics before the surgical ablation (if paroxysmal or persistent/long-standing persistent) and NYHA class seem to significantly predict relapses.

**Discussion**

The main finding of the present study is that concomitant surgical video-assisted left sided AF cryoablation creating a box lesion plus a mitral line during MIMVS resulted in favourable long-term sinus rhythm maintenance rates. Out of all, only three patients suffered symptomatic
recurrences, with ECG documentation of atypical atrial flutter in two cases and AF in one.

Following transcatheter ablation, patients resulted in sinus rhythm for the remaining follow-up.

Based on the present experience, therefore, in the remote case of symptomatic arrhythmia relapses, AF transcatheter ablation completing the surgical lesion set seems to easily avoid further recurrences.

The cut-and-sew Cox-Maze III procedure has been the gold standard for surgical AF treatment and has proved to be effective at eliminating the arrhythmia [18]. In recent years the development of ablation technologies has dramatically changed the field of AF surgical ablation by the introduction of new techniques and energy sources [8,9,10], allowing the replacement of the surgical incisions with the linear ablation lines, transforming a technically complex procedure into an accessible and minimally invasive approach. Differently from paroxysmal AF, in which triggers from the pulmonary veins play an important role in the initiation of AF, in non-paroxysmal AF, atrial substrate modification is thought to be highly relevant [19]. This is especially true for patients with valvular heart disease, in which a dilated and remodeled atrium is present. In fact, previous studies have shown that mechanisms as the elongation and stretch of the atrial fibers and the presence of atrial fibrosis are crucial in the initiation and maintenance of AF in such a patients [20]. Therefore, procedures aiming to isolate the PVs and to permanently modify the atrial substrate with the creation of transmural linear lesions are indeed promising.

The principal shortcomings of the use of minimal access techniques is that, due to potential suboptimal exposure, they may lead to an excess of simplification in the lesion set and potentially increase the possibility of conduction gaps. In this context, electrophysiological validation may permit electrical evaluation of the surgical ablation and allows to perform additional transcatheter ablation when necessary [21-23]. In fact, new hybrid approaches, combining minimally invasive surgical and percutaneous ablation are emerging [24].
Cryoablation during concomitant cardiac surgical procedures in sternotomy has appeared to be safe and effective [25]. Recently Gaita et al. reported that on patients with long-standing persistent AF and valvular heart disease, an hybrid approach including surgical cryoablation in sternotomy patients, consisting of pulmonary veins isolation and left atrial linear lesions combined with consequent transcatheter radiofrequency ablation was highly effective in maintaining very long-term follow-up SR [24]. However, in this experience 21.2% of the patients needed transcatheter ablation touch-ups to eliminate conduction gaps and to complete atrial lines. In the present study safe and reproducible transmural lesions set in a bloodless surgical field, was achieved by an endocardial argon-based cooling cryoablation system with a flexible, easily adaptable to patient’s anatomy cryoprobe (−160°C for 120 seconds) without the need of consequent transcatheter touch-ups in the vast majority of the cases.

Another important issue regards the thromboembolic complications during follow up. Literature reports an annual stroke rate in surgically treated valvular patients varying from 0.8% to 3%. This thromboembolic risk is higher if AF is present [26,27]. In the present population, three patients experienced a minor stroke and one patient had a stroke during the follow-up, giving an overall annual rate of 1.7%. The maintenance of SR seems, therefore, to act as a protective factor against stroke, even in a population with surgical valvular heart disease in which the risk for thromboembolic events is inherently increased.

Eventually, although surely influenced also by the concomitant MV surgery, minimally invasive AF cryoablation resulted to impact favourably the natural history of patients with MV disease and drug resistant symptomatic AF as shown by a significant reduction of NYHA class, and discontinuation of amiodarone and oral anticoagulants at follow up.

Conclusions
Surgical cryoablation concomitant to MIMVS resulted to be highly effective in maintaining SR and reducing AF burden on long-term follow-up. Based on the present study population a minimally invasive approach can also be offered to symptomatic AF patients. In the remote case of symptomatic arrhythmia relapses, AF transcatheter ablation may easily avoid further recurrences.

Study limitations

The following limitations must be taken in account. First, this report is a observational study and may therefore be biased by patient selection by physician in charge. Second, the limited sample size may have influenced the statistical power of the analysis. Third the limited clinical events did not permit multivariate analysis to detect independent inference of the study parameters. Fourth, the follow-up of our study was mostly ECG-based. Being aware that a monitoring based on serial 24h ECG Holter tracings or, even better, implantable recorders would be more accurate, in a mostly persistent AF setting, consideration of any AF relapse, also those present only once during the follow up should limit event underestimation. Eventually, given that the surgical approach described is the standard and the only performed for this specific indication in our Center, no comparison group is available.

References


Fiorenzo Gaita, MDemail, Elisa Ebrille, MD, Marco Scaglione, MD, Domenico Caponi, MD, Lucia Garberoglio, MD, Laura Vivalda, MD, Alessandro Barbone, MD, PhD, Roberto Gallotti, MD. Very Long-Term Results of Surgical and Transcatheter Ablation of Long-Standing Persistent Atrial Fibrillation The Annals of Thoracic Surgery Volume 96, Issue 4, Pages 1273–1278.


**Figure Legends**

**Central Picture (same as Fig. 2):** Study flow chart. AF: atrial fibrillation; EP: electrophysiological.

**Figure 1.** Anatomy of the left atrium following a para-septal atriotomy for exposure of the mitral valve using a left atrial lift system. Cryoablation lesion set performed in the study population connected to the left atriotomy thus creating a "box lesion" plus the mitral cryoline. SVC, superior vena cava; LIPV, left inferior pulmonary vein; LSPV, left superior pulmonary vein; RSPV, right superior pulmonary vein; RIPV, right inferior pulmonary vein; IVC, inferior vena cava. (Modified from Illustrated techniques for performing the Cox-Maze IV procedure through a right mini-thoracotomy, RJ Damiano Jr et al, ACS Vol 3, No 1)

**Figure 2.** Study flow chart. AF: atrial fibrillation; EP: electrophysiological.

**Figure 3.** (A) Echocardiographic parameters and functional class at baseline and end of follow-up within patients completing the 3.4 ±2.0 year follow-up. P value by Pearson Chi-Square/Fisher's Exact Test or ANOVA. LV EF, left ventricular ejection fraction; AP, antero-posterior; SI, supero-inferior; PAPs, systolic pulmonary artery pressure; NYHA, New York Heart Association functional class. (B) Medications at discharge and end of follow-up in patients completing the 3.4 ±2.0 year follow-up. P value by McNemar's test. ACE-i, angiotensin-converting-enzyme inhibitor; OAC, oral anticoagulation. * indicates comparison between pre-surgery and follow-up.

**Figure 4.** 3D electroanatomic reconstruction views: (A) Anteroposterior and leftlateral 3-D electroanatomic reconstruction view of the left atrium and pulmonary veins showing site of radiofrequency ablation (red dots) from the anterior portion of right superior pulmonary vein and the septal mitral isthmus and from the left inferior pulmonary vein and the lateral mitral isthmus. (B) Posteroanterior and right oblique (30°) 3-D electroanatomic reconstruction view of the left atrium and pulmonary veins showing absence of electrical activity on all the posterior wall (effect of surgical "box lesion"; upper part) and site of radiofrequency ablation (white dots) at the anterior
portion of the right superior pulmonary vein (site of conduction gap; lower part). (C)
Anteroposterior and left lateral 3-D electroanatomic reconstruction view of the left atrium and pulmonary veins showing the electrophysiological substrate and the site of radiofrequency ablation (red dots).

**Figure 5.** Kaplan Meier curves for survival free from AF (persistent AF; persistent and/or paroxysmal AF).
Figure 1.
Figure 2.

- 68 patients
  - 7 (10.3%) deaths
  - 1 (1.5%) converted to full sternotomy
  - 60 (88.2%) completed follow-up
    - 48 (80.0%) stable Sinus Rhythm
    - 12 (20.0%) AF relapses
      - 5 (41.7%) persistent relapses
        - 1 (20.0%) EP study and ablation
      - 7 (58.3%) paroxysmal relapses
        - 2 (28.6%) EP study and ablation
Figure 3.

(a) Bar chart showing comparison of left atrial AP maximum diameter (mm) and left atrial SI maximum diameter (mm) between pre-surgery and at follow-up. Pre-surgery values: LV EF (%) 56.8 ± 9.5, Left atrial AP maximum diameter 54.5 ± 10.7 mm, Left atrial SI maximum diameter 65.2 ± 11.2 mm, PAPs (mmHg) 46.0 ± 13.5, NYHA >1 (N) 57. At follow-up: LV EF (%) 55.0 ± 9.6, Left atrial AP maximum diameter 49.2 ± 7.2 mm, Left atrial SI maximum diameter 66.8 ± 6.6 mm, PAPs (mmHg) 36.1 ± 10.9, NYHA >1 (N) 8.

(b) Bar chart showing comparison of other parameters: beta-blockers (9.4), sotalol (6.3), amiodarone (9.4), ACE-i (56.3), OAC* (56.4), antiaggregants* (39.3) at discharge and follow-up (mean follow-up 3.4 ± 2.0 years). At discharge: beta-blockers (9.4), sotalol (6.3), amiodarone (56.3), ACE-i (46.9), OAC* (84.6), antiaggregants* (7.1). At follow-up: beta-blockers (68.8), sotalol (9.4), amiodarone (18.8), ACE-i (28.1), OAC* (56.4), antiaggregants* (39.3).
Figure 5.